Carl Diedrich Schlenkhoff

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig et al. · Oncotarget · 2016 · 285 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 173 citations

Medicine, Oncology, Pharmacology +17

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Hojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers et al. · Oncotarget · 2017 · 84 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer

Xiao X. Wei, Carl Diedrich Schlenkhoff, Bettina Schwarz et al. · Clinical Nuclear Medicine · 2017 · 37 citations

Medicine, Oncology, Radiation Oncology +17

Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer

Carl Diedrich Schlenkhoff, Florian Gaertner, Markus Essler et al. · Clinical Nuclear Medicine · 2016 · 23 citations

Medicine, Nuclear Medicine, Oncology +17